African Swine Fever (ASF) is one of the most important viral diseases affecting swine, with a serious socio-economic impact. It is present in more than 13 countries in Europe (10 in the EU), 28 sub-Saharan African countries, and 2 Asian countries, China and Mongolia. No vaccine is available and recent incursions in Europe and Asia are jeopardizing the pig industry worldwide. Control of ASF is based on early diagnosis and the implementation of strict sanitary measures. However, measures taken by affected countries have not been sufficient to stop spread. The objective of VACDIVA is to solve the ASF problem in Europe and affected countries through innovation efforts. VACDIVA will provide (1) Three safe and effective pilot vaccines for wild boar and domestic pigs ready for registration; (2) validated companion DIVA tests and 3) cost-benefit and effective surveillance and control-vaccination strategies, with field trials in Lithuania and Kenia. Two world leader companies in vaccine production and ASF diagnostic kits will provide production of the new vaccines and DIVA tests. Epidemiological modelling of worldwide scenarios will be offered in a portfolio of services to help animal health authorities control and eradicate the disease. This project will provide policy makers valuable decision support tools to better prevent and control ASF. VACDIVA counts with the expertise of two world ASF Reference Laboratories (OIE and FAO), the EU reference laboratory (EURL), six EU national Reference Laboratories (of 6 out of the 10 countries currently affected by ASF) and four prestigious ASF research institutions. Participation of Russian, Chinese and African laboratories will provide useful support, increasing acceptance of the vaccines. Active involvement of pig producers, agricultural associations and International agencies like FAO will enlarge the impact of communication, dissemination and training activities.